BridgeBio Pharma, Inc.（BBIO）の財務BBIOBridgeBio Pharma, Inc.

Evaluating the bottom line, BridgeBio Pharma, Inc. maintains a gross margin of 93.83%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -43.94%, while the net margin is -63.97%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively BBIO converts its operational activities into shareholder value.

In the context of the broader market, BBIO competes directly with industry leaders such as HALO and SMMT. With a market capitalization of $13.32B, it holds a leading position in the sector. When comparing efficiency, BBIO's gross margin of 93.83% stands against HALO's 77.40% and SMMT's N/A. Such benchmarking helps identify whether BridgeBio Pharma, Inc. is trading at a premium or discount relative to its financial performance.

BridgeBio has shown a gross margin of 93.83% in Q2 2026, indicating strong profitability potential. However, it has reported a negative net income of -155,891,000 USD in the same quarter, highlighting financial challenges.